Clinical trials: Transplantation, Liver
Fungal Infection
Multicenter Cohort Study of Invasive Fungal Filamentous Fungal Infections in Liver Transplant Patients
Invasive filamentous fungal infections (aspergillosis, scedosporiosis, mucormycosis, fusarium wilt) are frequent and serious in immunocompromised individuals and especially in organ transplant patients.
- Trial name
- FongiFoie (NCT05150327)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Liver Transplantation
Validity of Different Prognostic Models Assessing 1 Year Survival After Liver Transplantation
Validity of MELD vs MELD XI in assessing 1 year survival after living donor liver transplantation.
- Trial name
- ProgModels (NCT02412280)
- Testing
- retrospecive observational
- Volunteers
- 200 people
- Sponsor
- Mansoura University
HBsAg(+) Donor Kidney Allograft, HBsAg(-) Donor Kidney Allograft
Hepatitis B Antigen Kidney Graft Into Protective Level Hepatitis B Antibody Recipients
To determine the safety of using kidney organ from hepatitis B surface antigen positive donor, the author conducted the single-center, prospective study of the use of these kidneys for recipients who have protective level of…
- Trial name
- NCT02044588
- Testing
- HBsAg positive kidney allograft donor
- Where
- Thailand
- Volunteers
- 100 people
- Sponsor
- Chulalongkorn University
Liver Transplantation
Clinical Outcome of Liver Transplant Patients With Tacrolimus-based Immunosuppression
Genetic polymorphism and numerous clinical factors could influence tacrolimus pharmacokinetics, which led to large inter-and intra-individual variability.Since its narrow therapeutic range,predicting therapeutic outcome and…
- Trial name
- NCT03800576
- Where
- Taiwan
- Volunteers
- 113 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
Clemizole HCl for Subjects With Hepatocellular Carcinoma
This study is a phase IIa open label pilot study of up to six months treatment with clemizole hydrochloride (200 mg vs. 300 mg vs. 400 vs.
- Trial name
- NCT03069508
- Testing
- Clemizole Hydrochloride
- Where
- Turkey (Türkiye)
- Volunteers
- 12 people
- Sponsor
- Eiger Group International, Inc.
Fecal Microbiota Transplantation, Orthotopic Liver Transplantation
Fecal Microbiota Transplantation for the Prevention of Infectious Complications After Liver Transplantation
The increasing emergence and spread of MDRB represents a major public health problem, with higher mortality in patients experiencing infections.
- Conditions
- Fecal Microbiota Transplantation, Orthotopic Liver Transplantation, Multi-drug Resistant Bacteria
- Trial name
- NCT06782880
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- Italy
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepatitis C
Hepatitis C Positive Donor Into Hepatitis C Negative Recipients
Despite many efforts to increase the size of the donor pool, there is a large and growing disparity between the number of donor kidneys and livers available for transplantation and the number of patients on the transplant waiting…
- Trial name
- NCT03702218
- Testing
- Direct Acting Antivirals
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Evidence of Liver Transplantation
Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes
Type 1 diabetes mellitus (T1DM)is characterized by the autoimmune destruction of the pancreatic β cells; as a result, patients with T1DM are dependent on exogenous insulin to control their blood glucose continuously.
- Trial name
- NCT01157403
- Testing
- Autologous transplantation
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Lu Debin
Immunosuppression
Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients
The objective of this study is to determine the tolerability and safety of Myfortic in liver transplant patients. Patients receiving CellCept who have GI side effects will have CellCept discontinued and changed to Myfortic…
- Trial name
- NCT00336895
- Testing
- Myfortic
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Pittsburgh
Chronic Liver Disease and ACLF
Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry
Liver transplantation (LT) remains the ultimate option to cure intractable end stage liver disease. Nutritional deficiencies are very common among CLD patients and due to this these patients suffer from low bone mineral density…
- Trial name
- NCT07480057
- Testing
- no intervention
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatocellular Carcinoma, Liver Transplant
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC
HCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation is essential in the current…
- Trial name
- TEP CARE (NCT04792801)
- Testing
- PET TDM FDG-Choline
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- University Hospital, Lille
Liver Failure, End Stage Liver Disease
Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation
Rationale: Recent publications report good results of controlled donation after circulatory death (DCD) Maastricht category III liver transplantation when strict donor-recipient matching is applied and ischemia times are kept to…
- Conditions
- Liver Failure, End Stage Liver Disease, Biliary Tract Diseases
- Trial name
- DHOPE-DCD (NCT02584283)
- Testing
- Dual hypothermic oxygenated perfusion, Liver Assist®, Perfusion fluid
- Where
- 6 sites in Belgium, Netherlands and 1 more
- Volunteers
- 157 people
- Sponsor
- Robert J. Porte
Liver Transplantation
Ambisome in Liver Transplant Patients
In this study we are trying to find out the amount of a drug called Ambisome in the liver, the blood, the bile and the fatty tissues of the body.
- Trial name
- NCT00161356
- Testing
- Ambisome, Liver Biopsy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center, Houston
Acute-On-Chronic Liver Failure
SALT for Treatment of Patients With Early ACLF
ACLF is a syndrome characterized by rapid deterioration of liver function in chronic liver disease or undiagnosed chronic liver disease, with a high risk of short-term death.
- Trial name
- NCT06069037
- Testing
- sequential adult left lateral lobe liver transplantation (SALT)
- Where
- China
- Volunteers
- 10 people
- Sponsor
- RenJi Hospital
Colorectal Cancer, Metastatic Liver Cancer
Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
Multicentric prospective and observational study to assess the 5-year overall survival in a cohort of patients with unresectable liver-only colorectal metastases, well controlled by chemotherapy prior to liver transplantation.
- Conditions
- Colorectal Cancer, Metastatic Liver Cancer, Liver Metastases
- Trial name
- TRASMETIR (NCT04616495)
- Testing
- Liver transplantation
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario La Fe
Liver Transplantation
Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation
Currently, there is no treatment standard for use of anti-HCV (hepatitic C virus) medications for those preparing for a liver transplant.
- Trial name
- NCT01909401
- Testing
- boceprevir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Indiana University
Postoperative Graft Function
Hepatic Vein Flow During Orthotopic Liver Transplantation as Predictive Factor for Postoperative Graft Function
Hepatic vein flow (HVF) assessment using transesophageal echocardiography (TEE) has a potential to predict postoperative graft function in orthotopic liver transplant (OLT).
- Trial name
- NCT03814031
- Testing
- NO internvention
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Henry Ford Health System
Liver Disease (Alcoholic or Not), Liver Transplantation
Impact of Delta Model of End Stage Liver Disease (MELD) in High MELD Liver Transplant Recipients
Liver transplantation (LT) represents an important curative option for end stage liver disease such as decompensated cirrhosis, which remains a major challenge for today's health care system.
- Trial name
- HDMELD in LT (NCT07570901)
- Where
- 2 sites in Canada, Germany
- Volunteers
- 446 people
- Sponsor
- University of Jena
Sickle Cell Disease
Evaluation of Sickle Cell Liver Disease
Background: Sickle cell disease changes the shape of red cells. This makes them more likely to break down as they get stuck in small blood vessels.
- Trial name
- NCT01950429
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Cancer, Liver Transplant
FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation
Liver transplantation not only removes the liver tumor (seed) but also eliminates the underlying diseased liver (soil), making it an essential therapeutic approach for hepatocellular carcinoma (HCC).
- Trial name
- NCT06409637
- Testing
- FOLFOX4 regimen, lenvatinib
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University